Explain an Investment Process Without Turning It Into a Promise
Give institutional sales teams a disciplined way to describe process, risk, and evidence.
Institutional buyers often ask, “Why should this process work?” The question invites a clear explanation, but it does not authorize a prediction. Strong salespeople describe what the team does, the evidence available to examine it, and the risks or limits the buyer should consider. They leave performance conclusions to the client’s own review.
Structure the answer around observable decisions. Explain the stated research inputs, who makes portfolio decisions, how ideas are challenged, and how implementation is monitored. Then connect the description to the buyer’s question. For example: “You asked how the team avoids relying on one source of conviction. The approved process materials describe the independent review and escalation steps. Would it help to examine those with the analyst who leads that work?”
During a roleplay, an allocator says, “Your strategy seems defensive.” A weak answer is, “It will protect us in the next downturn.” A better response is, “Let’s clarify what defensive means in your framework. The strategy’s stated objective, historical materials, and risk disclosures can show how it has been managed, but they do not establish a future outcome.” The salesperson can then ask which risk measures and periods the allocator intends to review.
Coach teams to remove causal shortcuts such as “therefore it will outperform” or “this guarantees resilience.” Replace them with language grounded in sources: “The team documents this discipline in the investment memo,” or “that question should be addressed through the approved reporting.” Before a meeting, have the rep identify three process claims, the approved evidence behind each, and one limitation to state plainly. Accurate positioning earns more trust than a confident forecast.
Practice these next
A careful way for institutional sales teams to handle capacity questions using approved evidence.
Guide institutional sales teams through a careful conversation about a concentrated legacy holding.
Guide institutional sales teams through early fee questions without inventing commercial terms.
Guide an insurer duration discussion toward documented assumptions and the right diligence owners.
Use transparent, documented communication when a client asks about a process update.
Teach institutional sales teams to map stakeholders without assuming influence.